<DOC>
	<DOCNO>NCT01188577</DOCNO>
	<brief_summary>This study examine pharmacokinetic profile Armstrong 's proposed Epinephrine Inhalation Aerosol USP , HFA-MDI ( E004 ) , use stable isotope deuterium-labeled epinephrine ( epinephrine-d3 ) differentiate administer drug endogenous epinephrine , healthy male female adult volunteer . The current study design thorough evaluation E004 Pharmacokinetics . Safety E004 also evaluate , augment dose condition .</brief_summary>
	<brief_title>Epinephrine Inhalation Aerosol USP , HFA-MDI Study Assessment Pharmacokinetics</brief_title>
	<detailed_description>E004 formulate epinephrine free base active ingredient , hydrofluoroalkane ( HFA-134a ) propellant . In order differentiate inhale epinephrine fluctuating background endogenous epinephrine 1 , stable-isotope deuterium ( 2H ) label epinephrine ( epinephrine-d3 ) preparation use formulate E004 inhaler , denote E004-d3 . PK E004 125 mcg epinephrine-d3 per inhalation , compare currently market , non-labeled , Epinephrine-CFC MDI Reference Control ( 220 mcg per inhalation ) . This study randomize , evaluator-blind , single dose , two-arm , crossover , PK study , conduct ~18 healthy , male female , adult volunteer . PK study use E004-d3 125 mcg per inhalation ( Arm T ) . A currently market , non-labeled , Epinephrine CFC-MDI use Reference Control ( Arm C ) .</detailed_description>
	<mesh_term>Respiratory Sounds</mesh_term>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Generally healthy screening ; No clinically significant respiratory , cardiovascular systemic organic illness ; Body weight ≥ 50 kg men ≥ 45 kg woman , Sitting blood pressure ≤ 135/90 mm Hg ; Demonstrating negative HIV , HBsAg HCVAb screen test ; Women childbearing potential must nonpregnant , nonlactating , practice clinically acceptable form birth control ; Properly consent Other criterion apply A smoking history ≥10 packyears , smoke within 6 month ; Upper respiratory tract infection within 2 wk , low respiratory tract infection within 4 wk , prior Screening ; Any current recent respiratory condition might significantly affect pharmacodynamic response study drug ; Known intolerance hypersensitivity study MDI ingredient ; Having investigational study , donate blood , last 30 day ; Other Criteria Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchospasm</keyword>
	<keyword>wheeze</keyword>
	<keyword>shortness breath</keyword>
</DOC>